Effect of simvastatin on markers of triglyceride-rich lipoproteins in familial hypercholesterolaemia

European Journal of Clinical Investigation

Volumn 32, Issue 7, 2002, Pages 493-499

  Dane Stewart, C A ^a   Watts, Gerald F ^a,b   Mamo, J C L ^c   Barrett, P H R ^a   Martins, I J ^a   Dimmitt, S B ^a   Redgrave, T G ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b ROYAL PERTH HOSPITAL   (Australia)

^c Royal Perth Hospital ^*

Author keywords

Apolipoprotein B 48; Chylomicron remnants; Fractional catabolic rate; Heterozygous familial hypercholesterolaemia; Remnant like particle cholesterol; Simvastatin

Indexed keywords

APOLIPOPROTEIN B48; BIOLOGICAL MARKER; CARBON 13; CARBON DIOXIDE; CHOLESTEROL DERIVATIVE; CHOLESTEROL OLEATE; CHYLOMICRON; LIPOPROTEIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; BREATH ANALYSIS; CATABOLISM; CHEMOLUMINESCENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; DRUG EFFECT; DRUG MECHANISM; EMULSION; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HETEROZYGOTE; HUMAN; ISOTOPE LABELING; KINETICS; LIPID ANALYSIS; LIPID BLOOD LEVEL; LIPID METABOLISM; LIVER CLEARANCE; LIVER METABOLISM; LONG TERM CARE; MALE; MATHEMATICAL MODEL; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; SEPARATION TECHNIQUE; SHORT COURSE THERAPY; UPREGULATION; WESTERN BLOTTING;

APOLIPOPROTEIN B-48; APOLIPOPROTEINS B; BIOLOGICAL MARKERS; BREATH TESTS; CARBON ISOTOPES; CHOLESTEROL; CHOLESTEROL, LDL; CHYLOMICRONS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; LIPOPROTEINS; MALE; MIDDLE AGED; SIMVASTATIN; TRIGLYCERIDES;

EID: 0037002880     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2002.01012.x     Document Type: Article

References (35)

1. Simons LA, Dwyer T, Simons J, Berstein L, Mock P et al. Chylomicrons and chylomicron remnants in coronary artery disease; a case control study. Atherosclerosis 1987;65:181-5.
2. Karpe F, Steiner G, Uffelman K, Olivecrona T, Hamsten A. Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis 1994;106:83-97.
3. Mamo JCL. Atherosclerosis as a post-prandial disease. Endocrinol Metab 1995;2:229-44.
4. Dane-Stewart CA, Watts GF, Mamo JCL, Dimmitt S, Barrett PHR, Redgrave TG. Elevated apolipoprotein B-48 and remnant-like particle-cholesterol in heterozygous familial hypercholesterolaemia. Eur J Clin Invest 2001;31:113-7.
5. Raal FJ, Pilcher G, Illingworth DR, Pappu AS, Stein EA et al. Expanded-dose simvastatin is effective in homozygous familial hypercholesterolaemia. Atherosclerosis 1997;135:249-56.
6. Hoogerbrugge N. Effects of atorvastatin on serum lipids of patients with familial hypercholesterolaemia. J Int Med 1998;244:143-7.
7. Smilde TF, van Wissen S, Wollersheim H, Trip MD, Kastelein JJP, Stalenhoef AFH. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001;357:577-81.
8. Aguilar-Salinas CA, Barrett H, Schonfeld G. Metabolic modes of action of the statins in hyperlipoproteinemias. Atherosclerosis 1998;141:203-7.
9. Bowler A, Redgrave TG, Mamo JCL. Chylomicron-remnant clearance in homozygote and heterozygote Watanabe-heritable-hyperlipidaemic rabbits is defective. Biochem J 1991;276:381-6.
10. Cooper AD. Hepatic uptake of chylomicron remnants. J Lipid Res 1997;38:2173-92.
11. Twickler ThB, Dallinga-Thie de Valk HW, Schreuder PCNJ, Jansen H, Castro Cabezas M, Erkelens DW. High dose of simvastatin normalises postprandial remnant-like particle response in patients with heterozygous familial hypercholesterolaemia. Arterioscler Thromb Vasc Biol 2000;20:2422-7.
12. Smith D, Proctor SD, Mamo JCL. A highly sensitive assay for quantitation of apolipoprotein B-48 using an antibody to human apolipoprotein B and enhanced chemiluminescence. Ann Clin Biochem 1997;34:185-9.
13. Leary ET, Wang T, Baker DJ, Cilla DD, Zhong J et al. Evaluation of an immunoseparation method for the quantitative measurement of remnant-like particle cholesterol in serum and plasma. Clin Chem 1998;44:2490-8.
14. Smith D, Watts GF, Dane-Stewart C, Mamo JCL. Postprandial chylomicron response may be predicted by a single measurement of plasma apolipoprotein B-48 in the fasting state. Eur J Clin Invest 1999;29:204-9.
15. 2 breath test to assess the metabolism of triglyceride-rich lipoprotein remnants in mice. J Lipid Res 1998;39:691-8.
16. Redgrave TG, Watts GF, Martins IJ et al. Chylomicron remnant metabolism in familial dyslipidaemias studied with a remnant-like emulsion breath test. J Lipid Res 2001;42:710-5.
17. Mahley RW, Innerarity TL. Lipoprotein receptors and cholesterol homeostasis. Biochim Biophys Acta 1983;737:197-222.
18. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolaemia. In: Stanbury JB, Wyngaarden JB, Fredrickson DS, eds.The Molecular and Metabolic Basis of Inherited Disease. 7th edn. New York: McGraw-Hill, 1995.pp.1981-2020.
19. Chan DC, Watts GF, Barrett PHR, Martins IJ, James AP et al. Effect of atorvastatin on chylomicron remnant metabolism in visceral obesity: a study employing a new stable isotope breath test. J Lipid Res 2002;43:706-12.
20. Mori TA, Croft KD, Puddey IB, Beilin LJ. Analysis of native and oxidised low-density lipoprotein oxysterols using gas chromatography-mass spectrometry with selective ion monitoring 1996. Redox Rep 1996;2:25-34.
21. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with Hhal. J Lipid Res 1990;31:545-8.
22. Nakajima K, Okzaki M, Tanaka A, Pullinger CR, Wang T et al. Separation and determination of remnant-like particles in human serum using monoclonal antibodies to apo B-100 and apo A-1. J Clin Ligand Assay 1996;19:177-83.
23. Mamo JCL, Smith D, Yu KCW, Kawaguchi A, Harada-Shiba M, Yamamura T et al. Accumulation of chylomicron remnants in homozygous subjects with familial hypercholesterolemia. Eur J Clin Invest 1998;28:379-84.
24. Cabezas MC, de Bruin TWA, Westerveld HE, Meijer E, Erkelens DW. Delayed chylomicron remnant clearance in subjects with heterozygous familial hypercholesterolaemia. J Int Med 1998;244:299-307.
25. Campos E, Nakajima K, Tanaka A, Havel RJ. Properties of an apolipoprotein E-enriched fraction of triglyceride-rich lipoproteins isolated from human blood plasma with a monoclonal antibody to apolipoprotein B-100. J Lipid Res 1992;33:369-80.
26. Watts GF, Cummings MH, Umplebly M, Quiney JR, Naoumova R, Thompson GR et al. Simvastatin decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia: pathophysiological and therapeutic implications. Eur J Clin Invest 1995;25:559-67.
27. Martins IJ, Hone E, Chi C, Seydel U, Martins RN, Redgrave TG. Relative roles of LDLr and LRP in the metabolism of chylomicron remnants in genetically manipulated mice. J Lipid Res 2000;42:205-13.
28. Dashti N, Smith EA, Alaupovic P. Increased production of apolipoprotein B and its lipoproteins by oleic acid in Caco-2 cells. J Lipid Res 1990;31:113-23.
29. Murthy S, Albright E, Mathur SN, Davidson NO, Field EJ. Apolipoprotein B mRNA abundance is decreased by eicosapentaenoic acid in Caco-2 cells. Effect on the synthesis and secretion of apolipoprotein B. Arterioscler Thromb 1992;12:691-700.
30. Allister E, Pal S, Mamo JCL. Sterol regulation of chylomicron synthesis and secretion in an intestinal epithelial cell model (CaCo-2). (Abstract) Atherosclerosis 2000;151:286.
31. Watts GF. Postprandial lipaemia in familial hypercholesterolaemia: clinical and metabolic significance. Atherosclerosis 2000;148:426-8.
32. Angerer P, von Schacky C. n-3 polyunsaturated fatty acids and the cardiovascular system. Curr Opin Lipidol 2000;11:57-63.
33. Gudnason V, Day INM, Humphries SE. Effect on plasma lipid levels of different classes of mutations in the low-density lipoprotein receptor gene in patients with familial hypercholesterolaemia. Arterioscler Thromb 1994;14:1717-22.
34. Sun XM, Neuwirth C, Patel DD, Knight BL, Soutar AK. with the Familial hypercholesterolaemia regression Study Group. Influence of genotype at the low density lipoprotein (LDL) receptor gene locus on the clinical phenotype and response to lipid-lowering drug therapy in heterozygous familial hypercholesterolaemia. Atherosclerosis 1998;136:175-85.
35. Heath KE, Gudnason V, Humphries SE, Seed M. The type of mutation in the low density lipoprotein receptor gene influences the cholesterol-lowering response of the HMG-CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolaemia. Atherosclerosis 1999;143:41-54.